Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a

Antioxidants and Redox Signaling

Volumn 18, Issue 11, 2013, Pages 1249-1262

  Saxena, Ashish ^a   Tammali, Ravinder ^a   Ramana, Kota V ^a   Srivastava, Satish K ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; DNA; EPIDERMAL GROWTH FACTOR; MICRORNA 21; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C FOS; PROTEIN C JUN; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION;

ALDEHYDE REDUCTASE; ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICRORNAS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; TRANSCRIPTION FACTOR AP-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874455699     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4643     Document Type: Article

References (46)

1. Accili D, and Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117: 421-426, 2004.
2. American Cancer Society: Cancer Facts and Figures 2011. Atlanta, Ga: American Cancer Society, 2011.
3. Brenner DA, O'Hara M, Angel P, Chojkier M, and Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature 337: 661-663, 1989.
4. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, and Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
5. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, and Croce CM. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005.
6. Chan JA, Krichevsky AM, and Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033, 2005.
7. Chiacchiera F, and Simone C. Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 5: 1030-1033, 2009.
8. Diederichs S, and Haber DA. Sequence variations of micro-RNAs in human cancer: Alterations in predicted secondary structure do not affect processing. Cancer Res 66: 6097-6104, 2006.
9. El-Kabbani O, and Podjarny A. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. Cell Mol Life Sci 64: 1970-1978, 2007.
10. Georgescu MM. PTEN Tumor Suppressor Network in PI3KAkt Pathway Control. Genes Cancer 1: 1170-1177, 2010.
11. Grivennikov SI, Greten FR, and Karin M. Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
12. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, and Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113, 2009.
13. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Mé-nard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, and Croce CM. Micro-RNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
14. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
15. Kent OA, and Mendell JT. A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196, 2006.
16. Klaunig JE, and Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239-267, 2004.
17. Kong Q, Beel JA, and Lillehei KO. A threshold concept for cancer therapy. Med Hypotheses 55: 29-35, 2000.
18. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, Wainscoat JS, and Hatton CS. Microrna expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 121: 1156-1161, 2007.
19. Maehama T, and Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378, 1998.
20. Matés JM, Segura JA, Alonso FJ, and Márquez J. Intracellular redox status andoxidative stress: Implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 82: 273-299, 2008.
21. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, and Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007.
22. Ramana KV. ALDOSE REDUCTASE: New Insights for an Old Enzyme. Biomol Concepts 2: 103-114, 2011.
23. Ramana KV, Tammali R, and Srivastava SK. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells. Mol Cancer Ther 9: 813-824, 2010.
24. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, and Croce CM. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24: 4677-4684, 2006.
25. Shaulian E, and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-136, 2002.
26. Shike M, Winawer SJ, Greenwald PH, Bloch A, Hill MJ, and Swaroop SV. Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 68: 377-385, 1990.
27. Si ML, Zhu S, Wu H, Lu Z, Wu F, and Mo YY. miR-21-mediated tumor growth. Oncogene 26: 2799-2803, 2007.
28. Slaby O, Svoboda M, Michalek J, and Vyzula R. MicroRNAs in colorectal cancer: Translation of molecular biology into clinical application. Mol Cancer 8: 102, 2009.
29. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, and Khuri FR. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8: 1178-1184, 2002.
30. Srivastava SK, Ramana KV, and Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26: 380-392, 2005.
31. Srivastava SK, Yadav UC, Reddy AB, Saxena A, Tammali R, Shoeb M, Ansari NH, Bhatnagar A, Petrash MJ, Srivastava S, and Ramana KV. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem Biol Interact 191: 330-338, 2011.
32. Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G, D'Esposito M, Di Lauro R, and Verde P. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 28: 73-84, 2009.
33. Tammali R, Ramana KV, Singhal SS, Awasthi S, and Srivastava SK. Aldose reductase regulates growth factorinduced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res 66: 9705-9713, 2006.
34. Tammali R, Saxena A, Srivastava SK, and Ramana KV. Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells. J Biol Chem 286: 24089-24100, 2011.
35. Tammali R, Srivastava SK, and Ramana KV. Targeting aldose reductase for the treatment of cancer. Curr Cancer Drug Targets 11: 560-571, 2011.
36. Terzić J, Grivennikov S, Karin E, and Karin M. Inflammation and colon cancer. Gastroenterology 138: 2101-2114, 2010.
37. Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S, Richardson M, Rigaill G, Parrini MC, Lucchesi C, Bellanger D, Stern MH, Dubois T, Sastre-Garau X, Delattre O, Vincent-Salomon A, and Mechta-Grigoriou F. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med 2: 211-230, 2010.
38. Valencia-Sanchez MA, Liu J, Hannon GJ, and Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-524, 2006.
39. Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene 26: 6738-6749, 2007.
40. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, and Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261, 2006.
41. Wan XW, Jiang M, Cao HF, He YQ, Liu SQ, Qiu XH, Wu MC, and Wang HY. The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol 129: 100-106, 2003.
42. Wang K, and Li PF. Foxo3a regulates apoptosis by negatively targeting miR-21. J Biol Chem 285: 16958-16966, 2010.
43. Wang Z, Li Y, and Sarkar FH. Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression. Curr Stem Cell Res Ther 5: 74-80, 2010.
44. Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, Mittal K, Soteropoulos P, and Wei JJ. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 46: 336-347, 2007.
45. Yang JK. FLIP as an anti-cancer therapeutic target. Yonsei Med J 49: 19-27, 2008.
46. Zafonte BT, Hulit J, Amanatullah DF, Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP, and Pestell RG. Cell-cycle dysregulation in breast cancer: Breast cancer therapies targeting the cell cycle. Front Biosci 5: D938-961, 2000.